Camurus AB: FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease
LUND, Sweden, Sept. 16, 2021 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for the company's
Van Keimpema Fredrik Joabsson Clin Gastroenterol Hepatol Fredrik Tiberg Gastroenterol Hepatol Drug Administration
Source: finanznachrichten.de